Stockholder Alert: Robbins LLP Informs Investors of the Anavex Life Sciences Corp. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Anavex Life Sciences Corp. (NASDAQ: AVXL) securities between November 26, 2025 and August 28, 2026, inclusive (the "Class Period"). Anavex describes itself as "a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders."

The complaint alleges that Anavex Life Sciences Corp. misled investors regarding its lack of adequate internal controls.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information.

Why Was Anavex Sued?

According to the complaint, during the Class Period, defendants failed to disclose that:

(1) Anavex lacked adequate internal controls;
(2) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and
(3) as a result, defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Why Did Anavex Stock Drop?

Plaintiff alleges that on April 30, 2026, Anavex filed a current report on Form 8-K with the Securities and Exchange Commission ("SEC"), that stated that a special committee composed of independent directors of the Board of Directors terminated the employment of the Company's Chief Executive Officer, Christopher Missling, PhD, for, among other things, conduct that was inconsistent with Company policy. On this news, the price of Anavex stock declined by 0.59% on May 6, 2026.

On May 11, 2026, the Company filed with the SEC a notification of late filing on Form 12b-25 indicating that it was unable to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 by the prescribed May 11, 2026 due date. On this news, the Company's stock fell $0.18 per share, or 5.55%, to close at $3.06 on May 12, 2026.

The complaint continues, that on August 28, 2026, Anavex filed with the SEC an amended Annual Report on Form 10-K/A for the fiscal year ended September 30, 2025, indicating that "there was a material weakness in internal control over financial reporting that existed on September 30, 2025. Accordingly, the Company’s internal control over financial reporting as of September 30, 2025, as reported in its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (the “Original Form 10-K”) was not effective. In addition, the Company’s disclosure controls and procedures were not effective as of September 30, 2025, due to the material weakness in internal control over financial reporting as described above." The Company also filed an amended quarterly report on Form 10-Q/A for the fiscal quarter ended December 31, 2025, indicating that like the 10-K/A, the internal control over financial reporting as of December 31, 2025 10-Q/A were not effective.

Plaintiff alleges that also on August 28, 2026, the Company filed with the SEC its quarterly reports for the periods ending March 31, 2026 and June 30, 2026, which contained disclosures regarding statements on the Company’s clinical trials as well as its internal controls. On this news, Anavex stock fell $0.19 per share, or 6.35%, to close at $2.80 on August 31, 2026, the subsequent trading day.

Who May Be Eligible to Participate in the Anavex Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired Anavex Life Sciences Corp. securities between November 26, 2025 and August 28, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws.

What Is a Lead Plaintiff?

The lead plaintiff is a court-appointed investor who represents the interests of all class members throughout the litigation. Stockholders who wish to lead the class action should contact Robbins LLP.

Serving as lead plaintiff is not required to share in any potential recovery. Investors who do not seek appointment may remain absent class members if the case proceeds and later resolves successfully.

Does It Cost Anything to Participate?

No. Robbins LLP represents investors on a contingency fee basis.

Why Robbins LLP?

A recognized leader in shareholder rights litigation, Robbins LLP represents investors in securities fraud and shareholder derivative litigation. We have helped restore more than $2 billion in value to shareholders and secured some of the largest recoveries in shareholder derivative litigation history.

"Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently," said Brian J. Robbins, Founding Partner of Robbins LLP.

To be notified if a class action against Anavex Life Sciences Corp. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Contact Robbins LLP

Investors seeking additional information about the Anavex Life Sciences Corp. securities class action may contact Robbins LLP by submitting an inquiry, emailing attorney Aaron Dumas, Jr., or calling [phone].

Attorney Advertising. Past results do not guarantee a similar outcome.